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Vitamins;Abstract The present study was designed to explore the antioxidative status and circulating bio-
chemical markers having a potential role in the pathogenesis of ethambutol (EMB) induced toxic
optic neuropathy (TON) among diabetic and non-diabetic patients.
Fifty patients under complete therapy of EMB for tuberculosis were included in the present
study. Inclusion criteria for patients were to receive EMB everyday during treatment, a dose ofe; CAT,
bdulaziz
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Catalase;
GlutathioneFigure 1 Structure of ethambuto25 mg/kg for initial 2 months and 15 mg/kg during the rest of therapy period. We conducted color
vision and visual acuity test for all patients.
Fifteen out of ﬁfty EMB induced TON patients, were found to be diabetic. Color vision and
visual acuity test results were evaluated for diabetic and non-diabetic as well as twenty age matched
controls. The results demonstrated a signiﬁcant pattern of circulating biochemical markers between
the studied groups. Data regarding hematological (RBC, p value = 0.02; Hemoglobin, p
value = 0.02), hepatic (total bilirubin, p value = 0.01), renal (urea, p value = 0.03; creatinine, p
value = 0.007), lipid (total cholesterol, p value = 0.01; total triglycerides, p value = 0.03) and anti-
oxidative (superoxide dismutase, p value = 0.005; glutathione, p value = 0.02; catalase, p
value = 0.02) proﬁle showed a highly signiﬁcant difference among the studied groups specially
patients with diabetes. Malondialdehyde (MDA) level had gone signiﬁcantly up in diabetic TON
patients (p value = 0.02), in comparison to other antioxidants and vitamins (Vit). Vit-A, E, B1,
B12 and Zinc seem to be playing a major role in the pathogenesis of TON, specially Vit-E and
B1 surpassed all the antioxidants as having highly signiﬁcant inverse relationships with MDA
(MDA vs Vit-E, r= 0.676** and MDA vs Vit-B1, r= 0.724** respectively).
We conclude that during the ethambutol therapy the decreased levels of Vit-E and Vit-B1 possibly
play a role in the development of TON and may be used as therapeutic agents to lessen the delete-
rious effects of ethambutol.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Ethambutol is a highly speciﬁc chemical drug (PubChem
CID= 14052) (Fig. 1). It is speciﬁcally active against Myco-
bacterium, thus used for a treatment of tuberculosis and is con-
sidered to be very important drug. Like all other drugs EMB
also has few adverse side effects such as visual acuity, reduc-
tion of visual ﬁelds, scotomas, and problem in discriminating
between red and green color. About 2–6% patients of tubercu-
losis receiving EMB suffer from its serious side effect, toxic
optic neuropathy, which is dose as well as duration dependent
(Leibold, 1966; Kahana, 1987; Kho, 2004). Involvement of
optic nerve is not common during treatment of less than
2 months and visual function can be improved by discontinu-
ation of the drug while in some cases irreversibility has been
observed (Schild and Fox, 1991; Alvarez and Krop, 1993;
Cruz et al., 2010). Several studies indicated and conﬁrmed
toxic outcomes of EMB and a number of pathophysiological
mechanisms have been explained like disruption of mitochon-
drial complex IV, glutamate excitotoxicity and Zinc-associated
lysosomal membrane permeabilization.
The present study was designed to explore the antioxidative
status and circulating biochemical markers having a potential
role in the pathogenesis of EMB induced toxic optic
neuropathy.l (PubChem, CID 14052).2. Materials and methods
A total of ﬁfty patients taking complete therapy of EMB for
tuberculosis were eligible for inclusion in the study at the
Mayo Hospital, Lahore during March–September 2013.
Informed consent form was taken before the start of the study.
Detailed history, including clinical complications, smoking
habits and tobacco chewing was collected in a detailed ques-
tionnaire. Clinical diagnosis of the patient was also being
taken into consideration. Twenty controls, age matched
healthy individuals, were included in the study. The study
was approved by local ethics committee of the University of
Lahore, Pakistan.
2.1. Biochemical assays
Hepatic proﬁle [alanine transaminase (ALT), aspartate amino-
transferase, and alkaline phosphatase (ALP)] was estimated by
using the commercial Randox kits (Randox Laboratories,
Northern Ireland, UK). Serum bilirubin levels were measured
by the method of Jendrassik and Grof (1938). Hematological
proﬁle (Hemoglobin and RBC) was determined using cyan-
meth reagent (Van-Kampen and Zijlstra, 1965). Blood urea
was estimated by the kinetic method (Tiffany et al., 1972)
and creatinine levels by the rate of change in absorbance using
alkaline picrate (Larsen, 1972). Glutathione (GSH), catalase
(CAT), superoxide dismutase (SOD) and MDA levels were
estimated by the method of Ellman (Ellman, 1959), Aebi
(Aebi, 1974), Kakkar (Kakkar et al., 1984) and Ohkawa
(Ohkawa et al., 1979), respectively. Lipid proﬁle (total choles-
terol, low density lipoprotein, high density lipoprotein, and
total triglycerides) was determined using Friedewald’s formula
(Friedewald et al., 1972).
2.2. Statistical analysis
Results have been expressed as mean ± standard deviation.
The level of signiﬁcance was determined by one way analysis
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signiﬁcant difference were evaluated with ‘‘p’’ values and con-
sidered signiﬁcant at p< 0.05.
3. Results
Fifteen out of ﬁfty patients were found to be diabetic.
The visual acuity and color vision testing were explored in
the both groups including age matched controls (Table 1). The
mean age of evaluated patients was 20–41 years (control),
21–65 years (non-diabetics) and 20–65 years (diabetics).
Statistically signiﬁcant differences and consistent decreas-
ing pattern in Hemoglobin and RBC count between and within
the diabetic and non diabetic subjects (p= 0.001 and 0.021
respectively) were noted. The lowest value of RBC count
(3.80 · 106/mm3) was found in diabetic patients, however
minor reductions were reported for non-diabetic (5.4 · 106/
mm3) in comparison to control (5.97 · 106/mm3). The highest
values of ALT, aspartate aminotransferase, ALP and total bil-
irubin (65.73, 49.40, 376.19 and 2.10 IU/L respectively) were
observed in diabetic in comparison with that of control
(Fig. 2). The higher values of ALP (376.19 IU/L) compared
to ALT (65.73 IU/L) were also recorded in diabetic patients
and the ratio of ALP/ALT in the studied groups reﬂects the
progression of optic neurotoxicity in preponderance diabetics.
A decreasing trend of high-density lipoprotein levels was
recorded (control = 1.73 mg/dl; non-diabetic = 1.27 mg/dl
and diabetic = 1.17 mg/dl), however a reverse trend was found
for total cholesterol (control = 4.44 mg/dl; non-diabetic =
4.91 mg/dl and diabetic = 6.37 mg/dl), and low-density lipo-
protein (control = 2.31 mg/dl; non-diabetic = 2.83 mg/dl
and diabetic = 3.05 mg/dl) blood levels. Inconsistent pattern,
an increase in non-diabetic and a decrease in diabetic, of blood
triglycerides, creatinine, and urea levels was recorded within
the studied groups (Fig. 2).
Stress biochemical markers MDA, SOD, GSH and CAT
show a signiﬁcant pattern between and within the studied
groups. The consistent increasing trend in MDA levels (1.36,
5.28, 9.24 mmol/ml) was recorded in control, non diabetic
and diabetic groups respectively. However a clear consistent
decreasing trend in both SOD (0.73, 0.16 and 0.04 nmol/ml)
and CAT (4.27, 0.79 and 0.36 nmol/ml) was observed in the
studied groups. However, GSH showed inconsistent pattern.
Among vitamins and minerals, a consistent decreasing pat-
tern was reported between and within the studied groups. The
optimum values recorded for control, non-diabetic and dia-
betic patients were 686.45, 533.63 and 285.13 mmol/ml for
Vit-B12; 9.60, 8.20 and 6.47 mmol/ml for Vit-E; 1.58, 1.15,
and 0.42 mmol/ml for Vit-B1; 1.16, 0.88 and 0.67 mmol/ml
for Vit-A; and 12.30, 8.37 and 6.77 mmol/ml for Zinc.Table 1 Experimental design of patients with ethambutol induced
Groups Age (years) Baseline
visual acuity
Worst
visual acui
Control (n= 20) 20–41 20/15 Nil
Non-diabetic (n= 35) 21–65 20/30 20/150
Diabetic (n= 15) 20–65 20/40 20/2004. Discussion
Reactive oxygen species (ROS) under pathological conditions
is generated through mitochondrial respiratory chain and
its level increases intensely during environmental stress
(Devasagayam et al., 2004). The mechanisms of ROS mediated
damage and its involvement in disease progression are evident.
ROS production contributes to mitochondrial damage in
various diseases. Superoxide anion is the precursor of most
reactive oxygen species. Superoxide anion (O2
) is produced
by the one-electron reduction of molecular oxygen (O2) inside
the mitochondrion. Dismutation of superoxide anion gener-
ates hydrogen peroxide (H2O2), which may reduce to water
or to hydroxyl radical (OH) (Liochev and Fridovich, 1999).
Most of the ROS mediated diseases have a mitochondrial
component. Mitochondrial DNA translates few proteins which
are related to the electron transport chain, the main source of
ROS synthesis in cells.
Ethambutol is a vital medicine for the treatment of tuber-
culosis, however, a serious duration and dose-dependent side
effect named ‘‘toxic optic neuropathy’’ has been reported to
develop in 2–6% of patients receiving EMB (Citron and
Thomas, 1986). Short treatment duration i.e., less than
2 months is recommended to avoid any damage to optic
nerve, and discontinuation of the drug might help to
improve visual function, however in some cases, it is irre-
versible. Toxic effect of EMB has been established in many
studies and few pathophysiological mechanisms like disrup-
tion of mitochondrial complex IV, lysosomal membrane per-
meabilization and glutamate excitotoxicity have been
proposed to explain the EMB toxicity (Pierce and Denison,
1994). Because of better patient tolerance and easy adminis-
tration EMB became preferred choice for tuberculosis ther-
apy since last 25 years (Russo and Chaglasian, 1994;
Blumberg et al., 2003; Benson et al., 2003). It targets specif-
ically on propagating mycobacterial cells, and seems to
change the RNA synthesis pattern by stopping the mycolic
acid integration into the cell wall. Optic neuritis, the most
important side effect of this drug is, resulting in reduced
visual perception and color blindness (Kumar et al., 1993;
Chan and Kwok, 2006).
The results of the present study demonstrated a clear cut
picture regarding the circulating biochemical markers between
the studied groups i.e., control and patients with EMB induced
TON. Data regarding hematological, hepatic, renal, lipid and
antioxidative proﬁle show a highly signiﬁcant difference
among the studied groups specially patients with diabetes
(Chatterjee et al., 1986). Vitamins A, E, B1, B12 and Zinc seem
to be play a major role in the pathogenesis of TON compared
to superoxide dismutase, catalase and glutathione but Vit-Etoxic optic neuropathy.
ty
Baseline
color vision
Worst color vision Ocular
symptoms
14/14 Nil Nil
– 4/14 Blurred vision/disturbance
– 0/14 Worst blurred vision
Figure 2 Assessment of hematological proﬁle in ethambutol induced toxic optic neuropathy in non-diabetic and diabetic patients: (a)
showing increasing and decreasing levels of ALP and vitamin B12 in diabetic TON patients respectively, (b) showing increasing trend for
ALT and alkaline aminotransferase and decreasing trend for myoglobin and Zinc while urea level was inconsistent, (c) showing increased
value for total bilirubin, total cholesterol, total triglycerides, low-density lipoprotein, creatinine, and malondialdehyde while reduced value
for Hemoglobin, high-density lipoprotein, superoxide dismutase, catalase, vitamin-A, -E and -B1.
742 M. Rasool et al.and Vit-B1 surpassed all the antioxidants as they have a highly
signiﬁcant inverse relationships with malondialdehyde (MDA
vs Vit-E, r= 0.676** and MDA vs Vit-B1, r= 0.724**
respectively).5. Conclusion
In conclusion, prolonged ethambutol therapy decreases Vit-E
and Vit-B1 levels and possibly plays a role in the development
Role of biochemical markers in the pathogenesis of ethambutol induced toxic optic neuropathy 743of TON. Thus Vit-E and Vit-B1 may be used as therapeutic
agents to lessen the deleterious effects of EMB after conﬁrma-
tion. Data regarding hematological, hepatic, renal, lipid and
antioxidative proﬁle further revealed a highly signiﬁcant differ-
ence among the studied groups specially patients with diabetes.
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